Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: A comparative dosimetric study with early clinical outcome

被引:58
作者
Beriwal, S
Heron, DE
Kim, H
King, G
Shogan, J
Bahri, S
Gerszten, K
Lee, J
Kelley, J
Edwards, RP
机构
[1] Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA
[2] D3 Adv Radiat Planning, Pittsburgh, PA USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 64卷 / 05期
关键词
intensity-modulated radiation therapy; chemoradiation; vulva;
D O I
10.1016/j.ijrobp.2005.11.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To assess early clinical outcome of intensity-modulated radiation therapy (IMRT) in the treatment of vulvar cancer and compare dosimetric parameters with 3D conformal radiotherapy (3D CRT). Methods: Fifteen patients with vulvar cancer were treated with IMRT. Seven patients were treated with preoperative chemoradiation, and 8 patients were treated with adjuvant postoperative radiation therapy. Median dose was 46 Gy in the preoperative and 50.4 Gy in the postoperative group. Results: The mean volume of small bowel, rectum, and bladder that received doses in excess of 30 Gy with BIRT was reduced when compared with 3D CRT. Treatment was well tolerated, and only 1 patient had acute Grade 3 small-bowel toxicity. Median follow-up was 12 months. In the preoperative group, 5 patients (71%) had clinical complete response and 3 patients (42.8%) had pathologic complete response. In the adjuvant group, 2 patients had recurrences in the treatment field. No patients had late Grade 3 toxicity. The 2-year actuarial disease-specific survival was 100%. Conclusions: Intensity-modulated RT appears to offer advantages over 3D CRT treatment of vulvar cancer by elimination of dose modulation across overlapping regions and reduction of unnecessary dose to the bladder, rectum, and small bowel. Early results with a small number of patients show promising results, with a low incidence of severe toxicity. (c) 2006 Elsevier Inc.
引用
收藏
页码:1395 / 1400
页数:6
相关论文
共 37 条
[1]  
Ahamad A., 2002, International Journal of Radiation Oncology Biology Physics, V54, P42, DOI 10.1016/S0360-3016(02)03129-2
[2]  
Ahmad M, 2004, INT J RADIAT ONCOL, V60, pS484
[3]   Preliminary results of chemoradiation as a primary treatment for vulvar carcinoma [J].
Akl, A ;
Akl, M ;
Boike, G ;
Hebert, J ;
Graham, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :415-420
[4]  
ANDERSEN BL, 1983, OBSTET GYNECOL, V62, P457
[5]  
[Anonymous], 88 ANN M RAD SOC N A
[6]  
BORONOW RC, 1982, CANCER, V49, P1085, DOI 10.1002/1097-0142(19820315)49:6<1085::AID-CNCR2820490605>3.0.CO
[7]  
2-4
[8]   Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva [J].
Cunningham, MJ ;
Goyer, RP ;
Gibbons, SK ;
Kredentser, DC ;
Malfetano, JH ;
Keys, H .
GYNECOLOGIC ONCOLOGY, 1997, 66 (02) :258-261
[9]   RADICAL VULVECTOMY WITH POSTOPERATIVE IRRADIATION FOR VULVAR CANCER - THERAPEUTIC IMPLICATIONS OF A CENTRAL BLOCK [J].
DUSENBERY, KE ;
CARLSON, JW ;
LAPORTE, RM ;
UNGER, JA ;
GOSWITZ, JJ ;
ROBACK, DM ;
FOWLER, JM ;
ADCOCK, LL ;
CARSON, LF ;
POTISH, RA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (05) :989-998
[10]   PROLONGED CONTINUOUS-INFUSION CISPLATIN AND 5-FLUOROURACIL WITH RADIATION FOR LOCALLY ADVANCED-CARCINOMA OF THE VULVA [J].
EIFEL, PJ ;
MORRIS, M ;
BURKE, TW ;
LEVENBACK, C ;
GERSHENSON, DM .
GYNECOLOGIC ONCOLOGY, 1995, 59 (01) :51-56